Literature DB >> 1317054

A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system.

A Chaudhry1, K Oberg, E Wilander.   

Abstract

The expression of a proliferating antigen by Ki-67 immunohistochemistry was evaluated in 32 gastrointestinal carcinoids and in 5 pancreatic islet cell tumors. In the tissue sections the number of labelled nuclei was calculated per tumor area. The tumors were classified as low proliferating (less than 0.3 labelled cells/mm2), medium proliferating (0.3-1 labelled cells/mm2), and high proliferating (greater than 1 labelled cell/mm2). In 26 tumors obtained from patients receiving antitumor therapy (alpha-interferon) the proliferative activity was decreased. In treated midgut carcinoids the proliferative activity in metastatic tissue was significantly reduced (p less than 0.05). Though not statistically significant, primary midgut carcinoids collected from untreated patients displayed a lower proliferative activity than liver metastases. A survival analysis revealed that patients with tumors displaying low proliferative activity had a better survival than those with high proliferative activity (p less than 0.05). Single cell cytofluorometric DNA analyses showed regular diploid stem cell lines in the majority of tumors from untreated patients (9/11 cases). No correlation was found between the calculated proliferative activity and the DNA profile. The obtained results indicate that the expression of a proliferation antigen by Ki-67 immunohistochemistry can be used to evaluate the biological behavior of neuroendocrine tumors of the digestive system and predict survival.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317054     DOI: 10.1159/000217749

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

1.  Gastrinoma of the stomach: a case report.

Authors:  Andreas Tartaglia; Chiara Vezzadini; Silvia Bianchini; Paolo Vezzadini
Journal:  Int J Gastrointest Cancer       Date:  2005

2.  Advanced moderately differentiated neuroendocrine carcinoma of the rectum with favorable prognosis by postoperative chemoradiation.

Authors:  Hiroyuki Nojima; Kazuhiro Seike; Chihiro Kosugi; Takashi Shida; Keiji Koda; Kenji Oda; Shigeyuki Kamata; Hiroshi Ishikura; Masaru Miyazaki
Journal:  World J Surg Oncol       Date:  2010-04-17       Impact factor: 2.754

3.  p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells.

Authors:  C Bartz; C Ziske; B Wiedenmann; K Moelling
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

Review 4.  Criteria for malignancy in gastrointestinal endocrine tumors.

Authors:  Cesare Bordi; Tiziana D'Adda; Cinzia Azzoni; Silvia Pizzi; Lorena Bottarelli; Francesca Mormandi; Tommaso Antonetti; Tu Vinh Luong; Guido Rindi
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

5.  Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours.

Authors:  F Marrache; M P Vullierme; C Roy; Y El Assoued; A Couvelard; D O'Toole; E Mitry; O Hentic; P Hammel; P Lévy; P Ravaud; P Rougier; P Ruszniewski
Journal:  Br J Cancer       Date:  2006-12-12       Impact factor: 7.640

Review 6.  Biochemical diagnosis of neuroendocrine GEP tumor.

Authors:  K Oberg
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.